STOCK TITAN

XOMA Royalty Corporation - XOMA STOCK NEWS

Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.

XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in accelerating the development of groundbreaking therapeutic candidates. With an extensive portfolio of over 70 assets, XOMA acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. This unique model enables XOMA to provide non-dilutive, non-recourse funding to its partners, helping them advance their internal drug candidates or cater to general corporate needs.

Notably, XOMA has pioneered in the discovery and development of antibody therapeutics, leading to over 20 licenses producing milestone and royalty payments in the future. One key asset in their portfolio is X358, an allosteric monoclonal antibody aimed at treating hyperinsulinism by reducing insulin receptor activity.

XOMA has recently expanded its portfolio through strategic acquisitions. In January 2024, the company acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is an FDA-approved pain management option used in supervised medical settings. The agreement stipulates that XOMA will receive all royalties and milestones related to DSUVIA® until $20 million is accrued. Subsequently, royalties will be shared between XOMA and Talphera.

Further broadening its portfolio, XOMA acquired Kinnate Biopharma in April 2024, bringing additional assets into their royalty pipeline. Kinnate’s lead candidates include investigational pan-RAF inhibitor exarafenib and FGFR inhibitor KIN-3248, both targeting cancers with specific genetic alterations.

In April 2024, XOMA announced a $9 million milestone following the FDA approval of Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib), designed to treat pediatric low-grade glioma harboring BRAF alterations. This approval marks a significant addition to XOMA's cash flow and royalty income.

Additionally, XOMA's economic interest in three of Daré Bioscience's women's health products, including the FDA-approved XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream, 3.6%, signifies their commitment to addressing underrepresented therapeutic areas with significant growth potential.

As of their latest financial results, XOMA reported strong cash reserves and a growing portfolio of commercial and development-phase assets, ensuring long-term sustainability and value creation for shareholders. The company’s disciplined approach to capital deployment and strategic acquisitions highlights its commitment to enhancing human health through biotechnology advancements.

Rhea-AI Summary

XOMA Corporation (NASDAQ: XOMA) has announced that NIS793, an investigational antibody targeting Transforming Growth Factor Beta (TGFβ), has received Orphan Drug Designation from the FDA for pancreatic cancer treatment. This designation provides various benefits to encourage drug development for rare diseases. Upon regulatory approval of NIS793, XOMA could earn up to $445 million through milestone payments and receive tiered royalties on net product sales. However, efficacy and safety of NIS793 have not yet been established, and commercialization is not guaranteed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
Rhea-AI Summary

XOMA Corporation has acquired a royalty interest in Checkmate Pharmaceuticals’ therapy vidutolimod for $7 million, with potential sales milestones. Vidutolimod, a Toll-like receptor 9 agonist, aims to enhance the immune response against tumors, particularly in melanoma patients. The FDA has granted Fast Track and Orphan Drug designations for this treatment. XOMA stands to gain additional pre-commercial milestone payments of up to $25 million, positioned to benefit from future sales as Checkmate conducts multiple clinical studies to advance vidutolimod.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
Rhea-AI Summary

XOMA Corporation announced cash dividends for its preferred stockholders. Holders of 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.539 per share, while holders of 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.55833 per depositary share. The dividends are scheduled for payment on July 15, 2021, to shareholders of record as of July 2, 2021. XOMA also operates as a biotechnology royalty aggregator, acquiring potential future economics associated with drug candidates that have been licensed to other pharmaceutical firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
dividends
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) announced its licensees will present at the 2021 ASCO Annual Meeting from June 4-8. CEO Jim Neal expressed excitement over Novartis and AVEO's advancements with drug candidates NIS793 and ficlatuzumab, respectively, which are moving towards Phase 3 clinical programs. The presentations will showcase their investigational compounds, with efficacy and safety still unproven. Investors should note that there is no guarantee these drugs will reach commercial availability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences clinical trial
-
Rhea-AI Summary

XOMA reported a net loss of $7.4 million for Q1 2021, compared to $4.8 million in Q1 2020. The company's cash position improved to over $100 million following a $40 million Series B offering. As of March 31, XOMA held $67.8 million in cash, down from $84.2 million at the end of 2020. Total revenues decreased to $0.4 million from $0.8 million year-over-year. XOMA's portfolio now includes over 70 drug candidates, with recent acquisitions enhancing its pipeline. The board approved its first quarterly dividend payment for XOMAP, reflecting a strong financial posture amid an expanding asset base.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.73%
Tags
-
Rhea-AI Summary

XOMA Corporation has secured a $0.5 million milestone payment from Janssen Biotech for the first patient dosed in a Phase 3 clinical trial of a biologic asset. This marks the second molecule to reach Phase 3 since XOMA shifted to a biotech royalty aggregator model in 2017. The company anticipates further milestone payments and royalties upon successful marketing approval and commercialization of the asset. With a portfolio of advancements, XOMA is positioned to potentially enhance shareholder value through its partnered programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) has expanded its portfolio of potential future milestone and royalty assets by adding three Affimed N.V. innate cell engager (ICE®) programs. The additions include AFM13 and AFM24, both designed to harness the innate immune system against cancer. XOMA is eligible for undisclosed payments on future sales and milestone payments upon marketing approvals of these molecules. CEO Jim Neal expressed excitement over the maturation of legacy technology agreements into potential revenue-generating assets, enhancing value for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) announced the closing of its public offering of 1,600,000 depositary shares, representing a 1/1000th interest in its 8.375% Series B Cumulative Perpetual Preferred Stock. The offering raised gross proceeds of $40 million, netting approximately $38 million after fees. The funds will support a segregated dividend account and general corporate purposes, including future acquisitions related to drug development. Shares will trade on Nasdaq under the symbol 'XOMAO' soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
-
Rhea-AI Summary

XOMA Corporation has announced a public offering of 1,400,000 depositary shares at $25.00 each, raising $35.0 million in gross proceeds. Each share represents a 1/1000th interest in the company’s 8.375% Series B Cumulative Perpetual Preferred Stock. The offering, with a 30-day underwriter option for 200,000 additional shares, is set to close around April 9, 2021. Proceeds will fund a segregated dividend account and general corporate purposes, including future acquisitions related to drug development. Shares will trade under the symbol XOMAO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
Rhea-AI Summary

XOMA Corporation has initiated an underwritten public offering of depositary shares, each representing a 1/1000th fractional interest in its Series B Cumulative Perpetual Preferred Stock, priced at a liquidation preference of $25.00 per depositary share. The offering, led by several financial institutions, will use net proceeds primarily for funding acquisitions related to drug development programs. XOMA's offering is registered under an effective Form S-3 with the SEC, and additional shares may be available for purchase by underwriters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none

FAQ

What is the current stock price of XOMA Royalty Corporation (XOMA)?

The current stock price of XOMA Royalty Corporation (XOMA) is $27.13 as of December 20, 2024.

What is the market cap of XOMA Royalty Corporation (XOMA)?

The market cap of XOMA Royalty Corporation (XOMA) is approximately 302.6M.

What does XOMA Corporation do?

XOMA Corporation is a biotechnology royalty aggregator that acquires potential future economics from pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies.

What is XOMA’s business model?

XOMA provides non-dilutive, non-recourse funding to biotech companies in exchange for future economic rights to their therapeutic candidates, helping these companies advance their drug development.

What recent acquisitions has XOMA made?

In 2024, XOMA acquired an economic interest in DSUVIA® from Talphera, Inc., and Kinnate Biopharma, expanding its portfolio with new commercial and development-phase assets.

What are some key assets in XOMA's portfolio?

Key assets include DSUVIA® for pain management, OJEMDA™ for pediatric low-grade glioma, and women's health products like XACIATO™, Ovaprene®, and Sildenafil Cream from Daré Bioscience.

How does XOMA generate revenue?

XOMA generates revenue through milestone and royalty payments from the assets and therapeutic candidates it holds economic interests in.

What is the significance of XOMA’s investment in X358?

X358 is an allosteric monoclonal antibody that reduces insulin receptor activity, potentially having a major impact on the treatment of hyperinsulinism.

How does XOMA support biotech companies?

XOMA supports biotech companies by providing non-dilutive funding, allowing them to advance their drug candidates or support corporate initiatives without giving up equity.

What was the financial impact of XOMA’s acquisition of DSUVIA®?

XOMA will receive 100% of royalties and milestones from DSUVIA® sales until $20 million is accrued, after which royalties are shared with Talphera.

Who are some of XOMA’s partners?

XOMA has partnerships with various biotech and pharmaceutical companies, including Talphera, Alora Pharmaceuticals, Viracta Therapeutics, and Daré Bioscience.

What are XOMA's future plans for growth?

XOMA plans to continue its disciplined approach to capital deployment, acquiring economic interests in promising therapeutic candidates, and building a sustainable, cash-generating royalty portfolio.

XOMA Royalty Corporation

Nasdaq:XOMA

XOMA Rankings

XOMA Stock Data

302.58M
11.68M
0.84%
65.62%
1.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EMERYVILLE